Newly discovered weapons of bacterial self-defense take different approaches to achieving the same goal: preventing a virus from spreading through the bacterial population.

Mice with active infections had EcoHIV, the mouse equivalent of human HIV-1. Using CRISPR/Cas9, researchers were able to block replication of the virus and show they could potentially prevent ...

A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus. Traditional ...

Although antiretroviral therapies can contain HIV in the long term by preventing ... regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9 (Cas9).

Penn has undergone numerous advancements, including the creation of new undergraduate majors, campus development projects, ...

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

The latest price target for CRISPR Therapeutics (NASDAQ:CRSP) was reported by Barclays on May 9, 2025. The analyst firm set a price target for $42.00 expecting CRSP to rise to within 12 months (a ...